Vaxxinity, Inc. Class A Common Stock
VAXX
VAXX was delisted on the 8th of May, 2024.
17 hedge funds and large institutions have $102M invested in Vaxxinity, Inc. Class A Common Stock in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.4M |
| 2 |
SM
Scoggin Management
New York
|
+$2.91M |
| 3 |
Goldman Sachs
New York
|
+$2.29M |
| 4 |
Millennium Management
New York
|
+$900K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$704K |
Top Sellers
VAXX Hedge Fund Activity: Q4 2021 in Review
17 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Vaxxinity, Inc. Class A Common Stock (VAXX) for Q4 2021, worth a combined $102M.
Buyers outnumbered sellers: 17 funds opened new VAXX positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $10.4M.
- 17 institutional investors held Vaxxinity, Inc. Class A Common Stock (VAXX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $102M of Vaxxinity, Inc. Class A Common Stock stock for Q4 2021.
- 17 funds opened new Vaxxinity, Inc. Class A Common Stock positions in Q4 2021 and 0 closed out, a net change of +17 holders.
- The largest Vaxxinity, Inc. Class A Common Stock buyer in Q4 2021 was Adage Capital Partners, an estimated $10.4M added.
Based on aggregated 13F filings for Q4 2021.